Devyser Diagnostics (DVYSR) CMD 2024 summary

Strategic direction and business development

• Focus on hereditary diseases, oncology, and transplantation, with hereditary as the largest by revenue and transplantation as the fastest growing.

• Shift in R&D toward next-generation sequencing (NGS) and software, reducing emphasis on legacy fragment analysis while maintaining regulatory upgrades.

• Expansion of commercial organization and direct sales, especially in Europe and the U.S., supported by partnerships with Thermo Fisher and Illumina.

• Establishment of a CLIA-certified lab in the U.S. to drive both service and kit-based business models.

• Ongoing investment in regulatory approvals and infrastructure to support global growth.

Strategic vision and mission

• Aims to be a pioneering leader in diagnostic solutions, focusing on fast, accurate, and easy-to-use genetic tests for labs worldwide.

• Envisions universal access to personalized medicine through simplified and reliable genetic testing.

• Leverages NGS for highly accurate, rapid, and sensitive diagnostics.

Product innovation and pipeline

• Three new products planned for 2025: Genomic Blood Group Typing, Fetal Typing, and HLA Loss, all leveraging NGS technology.

• Enhanced software offerings, including AI-based tools for transplantation and transfusion medicine, and further IVDR compliance.

• Technical platform upgrade with absolute quantification of cell-free DNA, opening new opportunities in transplantation, oncology, and other fields.

• Over 30 active clinical studies worldwide, supporting product validation and market adoption.

• Strong scientific traction with increased publications and formation of a scientific advisory board.